BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)

BeOne Medicines (ONC) has 8 years of Long-Term Deferred Tax data on file, last reported at $2.0 billion in Q4 2023.

• Quarterly Long-Term Deferred Tax fell 2.38% year-over-year to $2.0 billion in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 billion (down 2.38% YoY) and the FY2023 annual result came in at $2.0 billion, down 2.38% from the prior year.
• Long-Term Deferred Tax retreated to $2.0 billion in Q4 2023 per ONC's latest filing, from $2.1 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $2.1 billion in Q4 2022 and bottomed at $30.5 million in Q1 2019.
• The 5-year median for Long-Term Deferred Tax is $66.0 million (2020), against an average of $328.5 million.
• The widest annual swing landed in 2019, when Long-Term Deferred Tax soared 155.83%; it then dropped 2.38% in 2023.
• Tracing ONC's Long-Term Deferred Tax over 5 years: stood at $37.9 million in 2019, then surged by 74.07% to $66.0 million in 2020, then surged by 61.98% to $106.8 million in 2021, then surged by 1846.59% to $2.1 billion in 2022, then fell by 2.38% to $2.0 billion in 2023.
• Per Business Quant, the three latest ONC Long-Term Deferred Tax figures stand at $2.0 billion (Q4 2023), $2.1 billion (Q4 2022), and $103.4 million (Q2 2022).

Peer Comparison